Most conversations about menopausal hormones focus on estrogen. Hot flashes, vaginal dryness, the clinical rationale for HRT: all framed around estrogen. Progesterone gets mentioned mainly as the hormone added to protect the uterus from unopposed estrogen's effects on the endometrium.

That framing misses most of what progesterone does. It has direct effects on the brain, sleep architecture, mood stability, anxiety levels, and the cardiovascular system; these effects are distinct from estrogen and many women experience losing them before any estrogen-related symptoms appear.

When Progesterone Falls First

During the reproductive years, progesterone is produced primarily in the corpus luteum, the temporary glandular structure that forms in the ovary after ovulation. Without ovulation, there is no corpus luteum. Without a corpus luteum, progesterone in the second half of the menstrual cycle drops close to zero.

Progesterone decline is tied to ovulation, not to estrogen production. In early perimenopause, estrogen levels can still be normal, occasionally even elevated, as the pituitary drives follicles harder in response to declining ovarian responsiveness. But ovulation becomes irregular. Some cycles are anovulatory. In those cycles, progesterone does not rise in the second half of the cycle.

Many women therefore enter a phase of relative progesterone deficiency while estrogen remains adequate or high.[1] Non-clinical literature often calls this estrogen dominance; the more precise term is progesterone insufficiency relative to estrogen. Either way, the hormonal imbalance begins with progesterone.

Progesterone's Effect on the Brain

Progesterone does not stay in the bloodstream unchanged. In the brain, it is converted by an enzyme (5-alpha reductase) into a metabolite called allopregnanolone. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors, the principal inhibitory receptors in the central nervous system.[2]

GABA is the main calming neurotransmitter. GABA-A receptors mediate the anxiolytic and sedating effects of several drug classes, including benzodiazepines, barbiturates, and anesthetic agents. Allopregnanolone acts at the same receptor sites through a different binding mechanism.

When progesterone and its conversion to allopregnanolone are adequate, there is a sustained positive influence on GABAergic inhibitory tone. The nervous system has a chemical substrate for calm. When progesterone falls, that substrate is removed: neural excitability rises, the threshold for anxiety lowers, and threat responses are less effectively suppressed.

The GABAergic mechanism for allopregnanolone is one of the most clearly characterised hormonal effects on the brain in the neuroscience literature.[2] It directly explains why early perimenopause, when estrogen may still be adequate but progesterone is declining, often presents with anxiety, sleep difficulty, and mood instability rather than hot flashes.

Progesterone and Sleep

Progesterone promotes sleep through two mechanisms: through the allopregnanolone pathway it increases GABAergic sedation and reduces sleep latency, and through a direct effect on the respiratory control centres in the brainstem it increases respiratory drive during sleep.[3] The respiratory mechanism has clinical consequences: progesterone is a respiratory stimulant, and its decline after menopause is one reason sleep apnea prevalence rises in postmenopausal women. Estrogen also supports upper airway muscle tone, and its decline compounds the risk, but these are distinct mechanisms.[4]

For perimenopausal women experiencing insomnia (particularly difficulty falling asleep or a busy, unquiet mind at bedtime), symptoms often appear at a stage when estrogen is still present but progesterone has become intermittent or low. This is not estrogen-related insomnia driven by night sweats. It is GABAergic withdrawal from a substrate that was previously reliable.

Progesterone and Mood

The relationship between progesterone, its metabolites, and mood is bidirectional and context-dependent. Adequate progesterone and allopregnanolone supports mood stability and reduces anxiety in most women. But some research on PMDD (premenstrual dysphoric disorder) has found that a subset of women has paradoxical sensitivity to allopregnanolone, experiencing increased anxiety and dysphoria from normal luteal-phase progesterone fluctuations rather than benefit.[5] This appears to be the same population that experiences mood worsening on certain progestogen-containing HRT regimens.

The distinction matters clinically. Most perimenopausal women experience mood instability from progesterone insufficiency and benefit from adequate progesterone or micronized progesterone supplementation. A smaller subset has allopregnanolone sensitivity and may have worse mood on certain progestogen formulations. When mood symptoms on HRT track specifically with the progestogen phase, the formulation, not the hormone class, is the likely issue.

Synthetic Progestins Are Not Progesterone

One of the most consequential misconceptions in HRT is treating synthetic progestins as equivalent to progesterone. They are not.

Synthetic progestins (norethisterone [NETA], medroxyprogesterone acetate [MPA], levonorgestrel, and others) were developed because natural progesterone is poorly absorbed orally and metabolised too rapidly for practical use as a once-daily tablet. Progestins solve these pharmacokinetic problems through structural modification.

The modifications that improve stability also change receptor binding profiles. Different progestins have varying degrees of androgenic, anti-androgenic, glucocorticoid, and anti-mineralocorticoid activity depending on molecular structure.[6] Norethisterone, widely prescribed in the UK, has androgenic activity. MPA, used extensively in the US and the subject of the Women's Health Initiative hormone arm, has distinct effects on breast tissue and cardiovascular markers compared to natural progesterone.

Micronized progesterone (Utrogestan in the UK and Europe; Prometrium in the US) uses natural progesterone processed into fine particles to improve bioavailability. It converts to allopregnanolone; synthetic progestins do not. It lacks the androgenic or glucocorticoid receptor activity of many progestins. Its breast cancer risk profile appears more favorable than synthetic progestins, based on observational data from the E3N cohort study.[7]

For mood, sleep, and anxiety, micronized progesterone is almost always better tolerated than synthetic progestins. For women who have experienced significant mood symptoms on progestogen-containing HRT, the first question is which progestogen they were taking, and the first trial should be switching to micronized progesterone before concluding that all progestogens cause problems.

Using Progesterone Without Estrogen

There is some evidence that oral progesterone can be used alone in perimenopause, without estrogen, for women who want relief from anxiety and sleep symptoms associated with early progesterone decline. A small randomised trial by Hitchcock and Prior (2012) found that oral progesterone 300 mg at bedtime reduced hot flash frequency and improved sleep in postmenopausal women, though the study was limited in size.[8] Bedtime dosing takes advantage of the sedative GABAergic effect.

This is not a standard first-line treatment, and progesterone alone does not provide uterine protection without estrogen. But it is a clinical option worth discussing with a menopause-informed prescriber, particularly for women in early perimenopause whose predominant symptoms are sleep and anxiety rather than vasomotor.

Reading Early Perimenopausal Symptoms

Understanding the timeline of progesterone decline relative to estrogen has practical implications for how symptoms are interpreted.

Sleep difficulty (particularly trouble falling asleep), increased anxiety, low-level restlessness, and worsened PMS in the second half of cycles: this cluster is consistent with intermittent progesterone insufficiency from anovulatory or short luteal phase cycles. Estrogen-driven symptoms (hot flashes, night sweats, vaginal dryness) may not be present yet. This phase can last several years before the more recognisable vasomotor symptoms appear. Having language for it makes it easier to describe accurately to a prescriber, opens the conversation about progesterone-specific treatment options, and avoids the years of misattribution that occur when these symptoms are labelled as anxiety disorder or poor sleep hygiene rather than hormonally driven.

When to Seek Clinical Review

Symptoms consistent with progesterone insufficiency (persistent insomnia, increased anxiety, mood instability, or worsening premenstrual symptoms in the second half of cycles) are worth raising with a menopause-informed clinician rather than simply monitoring. A prescriber familiar with perimenopause can assess the hormonal picture, rule out other causes, and discuss whether micronized progesterone or a change in progestogen formulation is appropriate. This is particularly relevant if symptoms are affecting daily functioning, if they have persisted across multiple cycles, or if a previous HRT regimen caused mood side effects that were never investigated beyond stopping the prescription.

References

[1] Prior, J. C. (1998). Perimenopause: The complex endocrinology of the menopausal transition. Endocrine Reviews, 19(4), 397–428. https://doi.org/10.1210/edrv.19.4.0341

[2] Lambert, J. J., Belelli, D., Peden, D. R., Vardy, A. W., Peters, J. A. (2003). Neurosteroid modulation of GABA-A receptors. Progress in Neurobiology, 71(1), 67–80. https://doi.org/10.1016/j.pneurobio.2003.09.001

[3] Driver, H. S., McLean, H., Kumar, D. V., Bhargava, R., McKibbon, A. E., Shapiro, C. M. (1996). The influence of the menstrual cycle on upper airway resistance and breathing during sleep. Sleep, 19(Suppl 2), S132–S134.

[4] Popovic, R. M., White, D. P. (1998). Upper airway muscle activity in normal women: Influence of hormonal status. Journal of Applied Physiology, 84(3), 1055–1062. https://doi.org/10.1152/jappl.1998.84.3.1055

[5] Backstrom, T., Andreen, L., Birzniece, V., et al. (2003). The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs, 17(5), 325–342. https://doi.org/10.2165/00023210-200317050-00003

[6] Schindler, A. E., Campagnoli, C., Druckmann, R., et al. (2003). Classification and pharmacology of progestins. Maturitas, 46(Suppl 1), S7–S16. https://doi.org/10.1016/j.maturitas.2003.09.014

[7] Fournier, A., Berrino, F., Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103–111. https://doi.org/10.1007/s10549-007-9523-x

[8] Hitchcock, C. L., Prior, J. C. (2012). Oral micronized progesterone for vasomotor symptoms: A placebo-controlled randomized trial in healthy postmenopausal women. Menopause, 19(8), 886–893. https://doi.org/10.1097/gme.0b013e318247f07a